{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:43:38Z","timestamp":1757313818116},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00105-018-4315-2","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T13:34:07Z","timestamp":1544016847000},"page":"51-63","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunadsorption in der Dermatologie","Immunoadsorption in dermatology"],"prefix":"10.1007","volume":"70","author":[{"given":"Franziska","family":"H\u00fcbner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kasperkiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enno","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"4315_CR1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/j.1744-9987.2012.01075.x","volume":"16","author":"D Meyersburg","year":"2012","unstructured":"Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D (2012) Immunoadsorption in dermatology. Ther Apher Dial 16:311\u2013320","journal-title":"Ther Apher Dial"},{"key":"4315_CR2","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","volume":"306","author":"GJ Anhalt","year":"1982","unstructured":"Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA (1982) Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N\u00a0Engl J Med 306:1189\u20131196","journal-title":"N Engl J Med"},{"key":"4315_CR3","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1172\/JCI116033","volume":"90","author":"N Domloge-Hultsch","year":"1992","unstructured":"Domloge-Hultsch N, Gammon WR, Briggaman RA, Gil SG, Carter WG, Yancey KB (1992) Epiligrin, the major human keratinocyte integrin ligand, is a\u00a0target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J\u00a0Clin Invest 90:1628\u20131633","journal-title":"J Clin Invest"},{"key":"4315_CR4","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jid.2017.03.037","volume":"137","author":"EN Heppe","year":"2017","unstructured":"Heppe EN, Tofern S, Schulze FS, Ishiko A, Shimizu A, Sina C et\u00a0al (2017) Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of\u00a0the\u00a0human disease. J\u00a0Invest Dermatol 137:1709\u20131718","journal-title":"J Invest Dermatol"},{"key":"4315_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00105-017-4089-y","volume":"69","author":"MM Holtsche","year":"2018","unstructured":"Holtsche MM, Zillikens D, Schmidt E (2018) Mucous membrane pemphigoid. Hautarzt 69:67\u201383","journal-title":"Hautarzt"},{"key":"4315_CR6","doi-asserted-by":"publisher","first-page":"17026","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz M, Ellebrecht CT, Takahashi H, Yamagami J, Zillikens D, Payne AS et\u00a0al (2017) Pemphigus. Nat Rev Dis Primers 3:17026","journal-title":"Nat Rev Dis Primers"},{"key":"4315_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/JID.2015.356","volume":"136","author":"M Kasperkiewicz","year":"2016","unstructured":"Kasperkiewicz M, Sadik CD, Bieber K, Ibrahim SM, Manz RA, Schmidt E et\u00a0al (2016) Epidermolysis bullosa acquisita: from pathophysiology to novel therapeutic options. J\u00a0Invest Dermatol 136:24\u201333","journal-title":"J Invest Dermatol"},{"key":"4315_CR8","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1172\/JCI116856","volume":"92","author":"Z Liu","year":"1993","unstructured":"Liu Z, Diaz LA, Troy JL, Taylor AF, Emery DJ, Fairley JA et al (1993) A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J\u00a0Clin Invest 92:2480\u20132488","journal-title":"J Clin Invest"},{"key":"4315_CR9","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00105-013-2599-9","volume":"64","author":"F Schulze","year":"2013","unstructured":"Schulze F, Kasperkiewicz M, Zillikens D, Schmidt E (2013) Bullous pemphigoid. Hautarzt 64:931\u2013943 (quiz 944\u20135)","journal-title":"Hautarzt"},{"key":"4315_CR10","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","volume":"2","author":"JC Roujeau","year":"1984","unstructured":"Roujeau JC, Guillaume JC, Morel P, Crickx B, Dalle E, Doutre MS et\u00a0al (1984) Plasma exchange in bullous pemphigoid. Lancet 2:486\u2013488","journal-title":"Lancet"},{"key":"4315_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","volume":"129","author":"JC Guillaume","year":"1993","unstructured":"Guillaume JC, Vaillant L, Bernard P, Picard C, Prost C, Labeille B et\u00a0al (1993) Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol 129:49\u201353","journal-title":"Arch Dermatol"},{"key":"4315_CR12","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/archderm.134.6.706","volume":"134","author":"H Schoen","year":"1998","unstructured":"Schoen H, Foedinger D, Derfler K, Amann G, Rappersberger K, Stingl G et\u00a0al (1998) Immunoapheresis in paraneoplastic pemphigus. Arch Dermatol 134:706\u2013710","journal-title":"Arch Dermatol"},{"key":"4315_CR13","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1610-0387.2007.06342.x","volume":"5","author":"D Zillikens","year":"2007","unstructured":"Zillikens D, Derfler K, Eming R, Fierlbeck G, Goebeler M, Hertl M et\u00a0al (2007) Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J\u00a0Dtsch Dermatol Ges 5:881\u2013887","journal-title":"J Dtsch Dermatol Ges"},{"key":"4315_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00403-009-1024-9","volume":"302","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, Zillikens D (2010) Immunoadsorption in dermatology. Arch Dermatol Res 302:241\u2013253","journal-title":"Arch Dermatol Res"},{"key":"4315_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1365-2133.2007.08358.x","volume":"158","author":"I Shimanovich","year":"2008","unstructured":"Shimanovich I, Nitschke M, Rose C, Grabbe J, Zillikens D (2008) Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 158:382\u2013388","journal-title":"Br J Dermatol"},{"key":"4315_CR16","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/j.1365-2133.2011.10585.x","volume":"166","author":"M Kasperkiewicz","year":"2012","unstructured":"Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J et\u00a0al (2012) Treatment of severe pemphigus with a\u00a0combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine\/mycophenolate mofetil: a\u00a0pilot study of 23 patients. Br J Dermatol 166:154\u2013160","journal-title":"Br J Dermatol"},{"key":"4315_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3389\/fmed.2018.00027","volume":"5","author":"M Kasperkiewicz","year":"2018","unstructured":"Kasperkiewicz M, Mook S\u2011C, Knuth-Rehr D, Vorobyev A, Ludwig RJ, Zillikens D et al (2018) IgE-selective Immunoadsorption for severe atopic dermatitis. Front Med (Lausanne) 5:27","journal-title":"Front. Med. (Lausanne)"},{"key":"4315_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2010.07.042","volume":"127","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M et al (2011) Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a\u00a0pilot study. J\u00a0Allergy Clin Immunol 127:267\u2013270.e1\u20136","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"4315_CR19","first-page":"1109","volume":"16","author":"F H\u00fcbner","year":"2018","unstructured":"H\u00fcbner F, Kasperkiewicz M, Knuth-Rehr D, Shimanovich I, H\u00fcbner J, S\u00fcfke S, et\u00a0al (2018) Adjuvant treatment of severe\/refractory bullous pemphigoid with protein A immunoadsorption. J\u00a0Dtsch Dermatol Ges 16(9):1109\u20131119","journal-title":"J\u00a0Dtsch Dermatol Ges"},{"key":"4315_CR20","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","volume":"381","author":"E Schmidt","year":"2013","unstructured":"Schmidt E, Zillikens D (2013) Pemphigoid diseases. Lancet 381:320\u2013332","journal-title":"Lancet"},{"key":"4315_CR21","first-page":"399","volume":"108","author":"E Schmidt","year":"2011","unstructured":"Schmidt E, Zillikens D (2011) The diagnosis and treatment of autoimmune blistering skin diseases. Dtsch Arztebl Int 108:399\u2013405, I\u2013III","journal-title":"Dtsch Arztebl Int"},{"key":"4315_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1001\/archderm.136.2.174","volume":"136","author":"E Schmidt","year":"2000","unstructured":"Schmidt E, Obe K, Br\u00f6cker EB, Zillikens D (2000) Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 136:174\u2013178","journal-title":"Arch Dermatol"},{"key":"4315_CR23","first-page":"833","volume":"13","author":"R Eming","year":"2015","unstructured":"Eming R, Sticherling M, Hofmann SC, Hunzelmann N, Kern JS, Kramer H et\u00a0al (2015) S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid. J\u00a0Dtsch Dermatol Ges 13:833\u2013844","journal-title":"J Dtsch Dermatol Ges"},{"key":"4315_CR24","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","volume":"159","author":"K Ishii","year":"1997","unstructured":"Ishii K, Amagai M, Hall RP, Hashimoto T, Takayanagi A, Gamou S et al (1997) Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J\u00a0Immunol 159:2010\u20132017","journal-title":"J Immunol"},{"key":"4315_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","volume":"19","author":"E Schmidt","year":"2010","unstructured":"Schmidt E, D\u00e4hnrich C, Rosemann A, Probst C, Komorowski L, Saschenbrecker S et\u00a0al (2010) Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients. Exp Dermatol 19:458\u2013463","journal-title":"Exp Dermatol"},{"key":"4315_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1046\/j.1468-3083.2002.00384.x","volume":"16","author":"K Hahn-Ristic","year":"2002","unstructured":"Hahn-Ristic K, Rzany B, Amagai M, Br\u00f6cker EB, Zillikens D (2002) Increased incidence of pemphigus vulgaris in southern Europeans living in Germany compared with native Germans. J\u00a0Eur Acad Dermatol Venereol 16:68\u201371","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4315_CR27","first-page":"434","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Br\u00f6cker E\u2011B, Zillikens D, Schmidt E (2009) Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J\u00a0Dtsch Dermatol Ges 7:434\u2013440","journal-title":"J Dtsch Dermatol Ges"},{"key":"4315_CR28","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","volume":"136","author":"F H\u00fcbner","year":"2016","unstructured":"H\u00fcbner F, Recke A, Zillikens D, Linder R, Schmidt E (2016) Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany. J\u00a0Invest Dermatol 136:2495\u20132498","journal-title":"J Invest Dermatol"},{"key":"4315_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","volume":"132","author":"JC Bystryn","year":"1996","unstructured":"Bystryn JC, Steinman NM (1996) The adjuvant therapy of pemphigus. An update. Arch Dermatol 132:203\u2013212","journal-title":"Arch Dermatol"},{"key":"4315_CR30","doi-asserted-by":"publisher","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM, Smeeth L, Hubbard R, Fleming KM, Smith CJP, West J (2008) Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study. BMJ 337:a180","journal-title":"BMJ"},{"key":"4315_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/157016309789869065","volume":"6","author":"M Kasperkiewicz","year":"2009","unstructured":"Kasperkiewicz M, Schmidt E (2009) Current treatment of autoimmune blistering diseases. Curr Drug Discov Technol 6:270\u2013280","journal-title":"Curr Drug Discov Technol"},{"key":"4315_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.jaad.2010.04.039","volume":"64","author":"LK Martin","year":"2011","unstructured":"Martin LK, Werth VP, Villaneuva EV, Murrell DF (2011) A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J\u00a0Am Acad Dermatol 64:903\u2013908","journal-title":"J Am Acad Dermatol"},{"key":"4315_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.autrev.2014.12.002","volume":"14","author":"AR Ahmed","year":"2015","unstructured":"Ahmed AR, Shetty S (2015) A comprehensive analysis of treatment outcomes in patients with pemphigus vulgaris treated with rituximab. Autoimmun Rev 14:323\u2013331","journal-title":"Autoimmun Rev"},{"key":"4315_CR34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","volume":"34","author":"E Schmidt","year":"2008","unstructured":"Schmidt E, Br\u00f6cker E\u2011B, Goebeler M (2008) Rituximab in treatment-resistant autoimmune blistering skin disorders. Clin Rev Allergy Immunol 34:56\u201364","journal-title":"Clin Rev Allergy Immunol"},{"key":"4315_CR35","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","volume":"389","author":"P Joly","year":"2017","unstructured":"Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S et al (2017) First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a\u00a0prospective, multicentre, parallel-group, open-label randomised trial. Lancet 389:2031\u20132040","journal-title":"Lancet"},{"key":"4315_CR36","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","volume":"389","author":"E Schmidt","year":"2017","unstructured":"Schmidt E (2017) Rituximab as first-line treatment of pemphigus. Lancet 389:1956\u20131958","journal-title":"Lancet"},{"key":"4315_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021","author":"DF Murrell","year":"2018","unstructured":"Murrell DF, Pe\u00f1a S, Joly P, Marinovic B, Hashimoto T, Diaz LA et\u00a0al (2018) Diagnosis and management of pemphigus: recommendations by an international panel of experts. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2018.02.021","journal-title":"J Am Acad Dermatol"},{"key":"4315_CR38","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1046\/j.1365-2133.2003.05302.x","volume":"148","author":"E Schmidt","year":"2003","unstructured":"Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M et\u00a0al (2003) Protein A immunoadsorption: a\u00a0novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 148:1222\u20131229","journal-title":"Br J Dermatol"},{"key":"4315_CR39","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2230.2006.02220.x","volume":"31","author":"I Shimanovich","year":"2006","unstructured":"Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Br\u00f6cker E\u2011B et al (2006) Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 31:768\u2013774","journal-title":"Clin Exp Dermatol"},{"key":"4315_CR40","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1046\/j.1365-2133.2003.05513.x","volume":"149","author":"M L\u00fcftl","year":"2003","unstructured":"L\u00fcftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M (2003) Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a\u00a0tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 149:598\u2013605","journal-title":"Br J Dermatol"},{"key":"4315_CR41","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1365-2133.2011.10732.x","volume":"166","author":"M Behzad","year":"2012","unstructured":"Behzad M, M\u00f6bs C, Kneisel A, M\u00f6ller M, Hoyer J, Hertl M et al (2012) Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 166:844\u2013852","journal-title":"Br J Dermatol"},{"key":"4315_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000480498","volume":"233","author":"C Schaffer","year":"2017","unstructured":"Schaffer C, Buclin T, Jornayvaz FR, Cazzaniga S, Borradori L, Gilliet M et al (2017) Use of dipeptidyl-peptidase IV inhibitors and bullous pemphigoid. Dermatology 233:401\u2013403","journal-title":"Dermatology"},{"key":"4315_CR43","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1111\/exd.13401","volume":"26","author":"A-K F\u00f6rsti","year":"2017","unstructured":"F\u00f6rsti A\u2011K, Huilaja L, Schmidt E, Tasanen K (2017) Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 26:1228\u20131234","journal-title":"Exp Dermatol"},{"key":"4315_CR44","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ajpath.2014.05.007","volume":"184","author":"FS Schulze","year":"2014","unstructured":"Schulze FS, Beckmann T, Nimmerjahn F, Ishiko A, Collin M, K\u00f6hl J et\u00a0al (2014) Fc\u03b3 receptors III and IV mediate tissue destruction in a\u00a0novel adult mouse model of bullous pemphigoid. Am J Pathol 184:2185\u20132196","journal-title":"Am J Pathol"},{"key":"4315_CR45","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.4049\/jimmunol.1100596","volume":"187","author":"M Hirose","year":"2011","unstructured":"Hirose M, Recke A, Beckmann T, Shimizu A, Ishiko A, Bieber K et\u00a0al (2011) Repetitive immunization breaks tolerance to type XVII collagen and leads to bullous pemphigoid in mice. J\u00a0Immunol 187:1176\u20131183","journal-title":"J Immunol"},{"key":"4315_CR46","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nm1496","volume":"13","author":"W Nishie","year":"2007","unstructured":"Nishie W, Sawamura D, Goto M, Ito K, Shibaki A, McMillan JR et\u00a0al (2007) Humanization of autoantigen. Nat Med 13:378\u2013383","journal-title":"Nat Med"},{"key":"4315_CR47","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1046\/j.1365-2249.2001.01503.x","volume":"124","author":"E Schmidt","year":"2001","unstructured":"Schmidt E, Reimer S, Kruse N, Br\u00f6cker EB, Zillikens D (2001) The IL-8 release from cultured human keratinocytes, mediated by antibodies to bullous pemphigoid autoantigen 180, is inhibited by dapsone. Clin Exp Immunol 124:157\u2013162","journal-title":"Clin Exp Immunol"},{"key":"4315_CR48","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau J\u2011C, Benichou J, Picard C, Dreno B, Delaporte E et al (2002) A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N\u00a0Engl J Med 346:321\u2013327","journal-title":"N Engl J Med"},{"key":"4315_CR49","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1111\/bjd.15649","volume":"177","author":"M Sticherling","year":"2017","unstructured":"Sticherling M, Franke A, Aberer E, Gl\u00e4ser R, Hertl M, Pfeiffer C et\u00a0al (2017) An open, multicentre, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone. Br J Dermatol 177:1299\u20131305","journal-title":"Br J Dermatol"},{"key":"4315_CR50","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","volume":"389","author":"HC Williams","year":"2017","unstructured":"Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E et al (2017) Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a\u00a0pragmatic, non-inferiority, randomised controlled trial. Lancet 389:1630\u20131638","journal-title":"Lancet"},{"key":"4315_CR51","first-page":"758","volume":"96","author":"A-K F\u00f6rsti","year":"2016","unstructured":"F\u00f6rsti A\u2011K, Jokelainen J, Timonen M, Tasanen K (2016) Risk of death in bullous pemphigoid: a retrospective database study in Finland. Acta Derm Venereol 96:758\u2013761","journal-title":"Acta Derm Venereol"},{"key":"4315_CR52","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.138.7.903","volume":"138","author":"B Rzany","year":"2002","unstructured":"Rzany B, Partscht K, Jung M, Kippes W, Mecking D, Baima B et\u00a0al (2002) Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 138:903\u2013908","journal-title":"Arch Dermatol"},{"key":"4315_CR53","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.jaad.2014.06.014","volume":"71","author":"M Kasperkiewicz","year":"2014","unstructured":"Kasperkiewicz M, Schulze F, Meier M, van Beek N, Nitschke M, Zillikens D et\u00a0al (2014) Treatment of bullous pemphigoid with adjuvant immunoadsorption: a\u00a0case series. J\u00a0Am Acad Dermatol 71:1018\u20131020","journal-title":"J Am Acad Dermatol"},{"key":"4315_CR54","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/jdv.12175","volume":"28","author":"M Kolesnik","year":"2014","unstructured":"Kolesnik M, Becker E, Reinhold D, Ambach A, Heim MU, Gollnick H et\u00a0al (2014) Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a\u00a0protocol without initial high dose or pulse steroid medication. J\u00a0Eur Acad Dermatol Venereol 28:771\u2013780","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4315_CR55","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000339071","volume":"224","author":"PA M\u00fcller","year":"2012","unstructured":"M\u00fcller PA, Br\u00f6cker EB, Klinker E, Stoevesandt J, Benoit S (2012) Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology 224:224\u2013227","journal-title":"Dermatology"},{"key":"4315_CR56","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000279318","volume":"220","author":"M Kasperkiewicz","year":"2010","unstructured":"Kasperkiewicz M, Meier M, Zillikens D, Schmidt E (2010) Linear IgA disease: successful application of immunoadsorption and review of the literature. Dermatology 220:259\u2013263","journal-title":"Dermatology"},{"key":"4315_CR57","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1007\/s00105-011-2189-7","volume":"62","author":"A Recke","year":"2011","unstructured":"Recke A, Shimanovich I, Steven P, Westermann L, Zillikens D, Schmidt E (2011) Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab. Hautarzt 62:852\u2013858","journal-title":"Hautarzt"},{"key":"4315_CR58","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2230.2009.03731.x","volume":"35","author":"M Kasperkiewicz","year":"2010","unstructured":"Kasperkiewicz M, Hoppe U, Zillikens D, Schmidt E (2010) Relapse-associated autoantibodies to BP180 in a\u00a0patient with anti-p200 pemphigoid. Clin Exp Dermatol 35:614\u2013617","journal-title":"Clin Exp Dermatol"},{"key":"4315_CR59","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1346-8138.2011.01376.x","volume":"39","author":"L Westermann","year":"2012","unstructured":"Westermann L, H\u00fcgel R, Meier M, Weichenthal M, Zillikens D, Gl\u00e4ser R et al (2012) Glucocorticosteroid-resistant pemphigoid gestationis: successful treatment with adjuvant immunoadsorption. J\u00a0Dermatol 39:168\u2013171","journal-title":"J Dermatol"},{"key":"4315_CR60","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1046\/j.1610-0387.2003.t01-1-03509.x","volume":"1","author":"S W\u00f6hrl","year":"2003","unstructured":"W\u00f6hrl S, Geusau A, Karlhofer F, Derfler K, Stingl G, Zillikens D (2003) Pemphigoid gestationis: treatment with immunoapheresis. J\u00a0Dtsch Dermatol Ges 1:126\u2013130","journal-title":"J Dtsch Dermatol Ges"},{"key":"4315_CR61","first-page":"27","volume":"9","author":"M Marker","year":"2011","unstructured":"Marker M, Derfler K, Monshi B, Rappersberger K (2011) Successful immunoapheresis of bullous autoimmune diseases: pemphigus vulgaris and pemphigoid gestationis. J\u00a0Dtsch Dermatol Ges 9:27\u201331","journal-title":"J Dtsch Dermatol Ges"},{"key":"4315_CR62","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1001\/archderm.143.2.192","volume":"143","author":"A Niedermeier","year":"2007","unstructured":"Niedermeier A, Eming R, Pf\u00fctze M, Neumann CR, Happel C, Reich K et al (2007) Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 143:192\u2013198","journal-title":"Arch Dermatol"},{"key":"4315_CR63","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.4049\/jimmunol.155.11.5449","volume":"155","author":"Z Liu","year":"1995","unstructured":"Liu Z, Diaz LA, Swartz SJ, Troy JL, Fairley JA, Giudice GJ (1995) Molecular mapping of a\u00a0pathogenically relevant BP180 epitope associated with experimentally induced murine bullous pemphigoid. J\u00a0Immunol 155:5449\u20135454","journal-title":"J Immunol"},{"key":"4315_CR64","first-page":"289","volume":"11","author":"I Kubisch","year":"2010","unstructured":"Kubisch I, Diessenbacher P, Schmidt E, Gollnick H, Leverkus M (2010) Premonitory epidermolysis bullosa acquisita mimicking eyelid dermatitis: successful treatment with rituximab and protein A immunoapheresis. Am J Clin Dermatol 11:289\u2013293","journal-title":"Am J Clin Dermatol"},{"key":"4315_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","volume":"4","author":"S Weidinger","year":"2018","unstructured":"Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD (2018) Atopic dermatitis. Nat Rev Dis Primers 4:1","journal-title":"Nat Rev Dis Primers"},{"key":"4315_CR66","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N (2016) Atopic dermatitis. Lancet 387:1109\u20131122","journal-title":"Lancet"},{"key":"4315_CR67","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jaci.2016.05.038","volume":"138","author":"H-H Wang","year":"1722","unstructured":"Wang H\u2011H, Li Y\u2011C, Huang Y\u2011C (1722) Efficacy of omalizumab in patients with atopic dermatitis: a\u00a0systematic review and meta-analysis. J\u00a0Allergy Clin Immunol 138:1719\u2013e1","journal-title":"J Allergy Clin Immunol"},{"key":"4315_CR68","doi-asserted-by":"publisher","first-page":"254","DOI":"10.3389\/fimmu.2018.00254","volume":"9","author":"M Kasperkiewicz","year":"2018","unstructured":"Kasperkiewicz M, Schmidt E, Ludwig RJ, Zillikens D (2018) Targeting IgE antibodies by Immunoadsorption in atopic dermatitis. Front Immunol 9:254","journal-title":"Front Immunol"},{"key":"4315_CR69","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1744-9987.12267","volume":"19","author":"G Daeschlein","year":"2015","unstructured":"Daeschlein G, Scholz S, Lutze S, Eming R, Arnold A, Haase H et\u00a0al (2015) Repetitive immunoadsorption cycles for treatment of severe atopic dermatitis. Ther Apher Dial 19:279\u2013287","journal-title":"Ther Apher Dial"},{"key":"4315_CR70","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jamadermatol.2014.2082","volume":"150","author":"M Kasperkiewicz","year":"2014","unstructured":"Kasperkiewicz M, S\u00fcfke S, Schmidt E, Zillikens D (2014) IgE-specific immunoadsorption for treatment of recalcitrant atopic dermatitis. JAMA Dermatol 150:1350\u20131351","journal-title":"JAMA Dermatol"},{"key":"4315_CR71","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.jaci.2016.01.016","volume":"137","author":"K Reich","year":"1884","unstructured":"Reich K, Deinzer J, Fiege A\u2011K, von Gruben V, Sack A\u2011L, Thraen A et al (1884) Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. J\u00a0Allergy Clin Immunol 137:1882\u2013e6","journal-title":"J Allergy Clin Immunol"},{"key":"4315_CR72","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2340\/00015555-2165","volume":"96","author":"A Zink","year":"2016","unstructured":"Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V et\u00a0al (2016) Targeting IgE in severe atopic dermatitis with a\u00a0combination of immunoadsorption and omalizumab. Acta Derm Venereol 96:72\u201376","journal-title":"Acta Derm Venereol"},{"key":"4315_CR73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00403-015-1606-7","volume":"308","author":"M Mersmann","year":"2016","unstructured":"Mersmann M, Dworschak J, Ebermann K, Komorowski L, Schlumberger W, St\u00f6cker W et\u00a0al (2016) Immunoadsorber for specific apheresis of autoantibodies in the treatment of bullous pemphigoid. Arch Dermatol Res 308:31\u201338","journal-title":"Arch Dermatol Res"},{"key":"4315_CR74","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/exd.12355","volume":"23","author":"J Langenhan","year":"2014","unstructured":"Langenhan J, Dworschak J, Saschenbrecker S, Komorowski L, Schlumberger W, St\u00f6cker W et\u00a0al (2014) Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins. Exp Dermatol 23:253\u2013259","journal-title":"Exp Dermatol"},{"key":"4315_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01935","author":"M Hofrichter","year":"2018","unstructured":"Hofrichter M, Dworschak J, Emtenani S, Langenhan J, Wei\u00df F, Komorowski L et\u00a0al (2018) Immunoadsorption of desmoglein-3-specific IgG abolishes the blister-inducing capacity of pemphigus vulgaris IgG in neonatal mice. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2018.01935","journal-title":"Front Immunol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-018-4315-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-018-4315-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T01:29:02Z","timestamp":1720834142000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-018-4315-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["4315"],"URL":"https:\/\/doi.org\/10.1007\/s00105-018-4315-2","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"5 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Schmidt, F.\u00a0H\u00fcbner, M.\u00a0Kasperkiewicz und D.\u00a0Zillikens haben Honorare und Reisekosten von der Fa. Fresenius Medical Care erhalten. E.\u00a0Schmidt, M.\u00a0Kasperkiewicz und D.\u00a0Zillikens haben Honorare und Reisekosten von der Fa. Miltenyi Biotech erhalten. E.\u00a0Schmidt und D.\u00a0Zillikens haben eine wissenschaftliche Kooperation mit den Firmen Fresenius Medical Care, Miltenyi Biotech und Euroimmun.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben. Im Falle von nicht m\u00fcndigen Patienten liegt die Einwilligung eines Erziehungsberechtigten oder des gesetzlich bestellten Betreuers vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}